| Table 2. Pattern of utilization of follitropin delta in Brazil – Cycle characteristics | ||||
| Variable | Oocyte donors (n=131) |
Oocyte cryopreservation (n=705) |
IVF (n=1448) |
All patients (n=2284) |
|---|---|---|---|---|
| Steroid priming · No · Oral contraceptives · Estradiol valerate · Norethisterone |
78 (59.5%) 24 (18.3%) 2 (1.5%) 27 (20.6%) |
427 (60.6%) 46 (6.5%) 28 (4%) 204 (28.9%) |
991 (68.4%) 77 (5.3%) 46 (3.2%) 334 (23.1%) |
1496 (65.5%) 147 (6.4%) 76 (3.3%) 565 (24.8%) |
| Phase of cycle · Follicular · Luteal · Second phase of duo-stim |
124 (94.7%) 7 (5.3%) 0 |
601 (85.2%) 101 (14.3%) 3 (0.4%) |
1296 (89.5%) 135 (9.3%) 17 (1.2%) |
2021 (88.5%) 243 (10.6%) 20 (0.9%) |
| Type of pituitary suppression · GnRH antagonist · Progestin · Others · Unknown data, due to cycle cancellation |
15 (11.5%) 104 (79.4%) 8 (6.1%) 4 (3.0%) |
327 (46.4%) 340 (48.2%) 2 (0.3%) 36 (5.1%) |
816 (56.3%) 546 (37.8%) 5 (0.3%) 81 (5.6%) |
1158 (50.7%) 990 (43.4%) 15 (0.6%) 121 (5.3%) |
| Prescription based on algorithm · Yes (Protocol 1) · No Protocol 2 Protocol 3 Protocol 4 Protocol 5 |
0 131 (100%) 13 (9.9%) 99 (75.6%) 0 19 (14.5%) |
17 (2.4%) 688 (97.6%) 130 (18.4%) 494 (70.1%) 44 (6.2%) 20 (2.8%) |
26 (1.8%) 1422 (98.2%) 195 (13.5%) 1126 (77.8%) 70 (4.8%) 31 (2.1%) |
43 (1.9%) 2241 (98.1%) 338 (14.8%) 1719 (75.2%) 114 (5%) 70 (3.1%) |
| Cycle cancellation before OPU · Poor response · Risk of OHSS |
4 (3.0%) 0 |
36 (5.1%) 0 |
81 (5.6%) 0 |
121 (5.3%) 0 |
| Ovulation trigger · hCG · GnRH agonist · Dual trigger |
n=127 1 (0.8%) 111 (87.4%) 15 (11.8%) |
n=669 49 (7.3%) 347 (51.9%) 273 (40.8%) |
n=1367 186 (13.6%) 576 (42.1%) 605 (44.2%) |
n=2163 236 (10.9%) 1034 (47.8%) 893 (41.3%) |
Data are presented as mean±standard deviation (SD).
Protocol 1 (algorithm)
Protocol 2 (non-algorithm monotherapy)
Protocol 3 (delta + hMG)
Protocol 4 (delta + rFSH/LH)
Protocol 5 (others)